Longitudinal measurements of CA125 taken during and at the end of chemotherapy treatment for patients with advanced ovarian cancer can identify the patients at a high risk of disease progression and death and provide an intuitive visual tool for monitoring and informing their prognoses. This evidence concerns the gene MUC16 and ovarian carcinoma.